Best of ASCO - 2014 Annual Meeting

 

Welcome

Advanced Disease

Gastrointestinal (Colorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.

Pashtoon Murtaza Kasi

e15065

A novel RAS internal tandem duplication involving the switch II domain disrupts GAP-binding and activates oncogenic signaling.

Emil Lou

e15069

A phase I clinical trial of fluorouracil (5-FU) + devimistat (CPI-613) combination in previously treated patients (pts) with metastatic colorectal cancer (MCR).

Caio Max Sao Pedro Rocha Lima

e15054

A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO).

Joleen Marie Hubbard

3557

A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic MSS colorectal cancer (CRC): A postoperative safety analysis.

Michael Frederick Bassetti

e15047

A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.

Arthur Winer

e15020

A phase II study of apatinib combined with S-1 in previously treated refractory metastatic colorectal cancer.

Ning Li

e15016

A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).

Aparna Raj Parikh

3514

A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).

Hirokazu Shoji

3538

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).

Stefan Kasper

TPS3617

A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.

Filippo Pietrantonio

3509

A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

Carl Christoph Schimanski

3537

A regulatory program that promotes metastasis in colorectal cancer (CRC) through modulation of mRNA stability.

Hani Goodarzi

3523

Add-on anti-vascularendothelial growth factor agents with the second-line chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized trials.

Feng-Che Kuan

e15059

Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): Clinical predictors of nonhematologic (nonhem) toxicity.

Liubov Yu Vladimirova

e15007

Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.

Madeleine Fish

3563

Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study.

Ibrahim Halil Sahin

e15029

Apatinib combined with Raltitrexed in patients with metastatic colorectal cancer after failure of standard therapy (AHEAD-311): A single-arm phrase II pilot trial.

Haiyan Si

e15008

Apatinib monotherapy for chemotherapy-refractory metastatic colorectal cancer: A multicenter, single-arm, prospective study.

Fen Wang

3527

Association between gene fusions and anti-EGFR resistance signature in colorectal cancer.

Thereasa A. Rich

3564

Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial.

Jin Li

e15012

Association of co-occuring mutations in exosomal DNA and clinical outcomes of patients with metastatic colorectal cancer.

Chuanhua Zhao

e15001

Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.

Lisa Salvatore

3550

Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.

James Isaacs

3552

CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).

Eric Xueyu Chen

3512

Cetuximab maintenance therapy in unresectable metastatic colorectal cancer patients with wild-type RAS and BRAF: A single-center retrospective study.

Tao Jiang

e15004

cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study.

Alexandre Harle

3542

Characteristics and outcomes of patients with colorectal cancer and bone metastasis.

Faisal Shahjehan

e15063

Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).

Maria Alessandra Calegari

3556

Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients.

Pashtoon Murtaza Kasi

3566

Circulating tumor DNA-based mutational landscape of advanced colorectal cancer.

Fang Yan

e15034

Clinical efficacy and safety evaluation of nimotuzumab combined with chemotherapy in the treatment of advanced colorectal cancer: A retrospective analysis.

Sai-xi Bai

e15009

Clinical significance of ZHX2 in colitis and colorectal carcinogenesis.

Yonghua Bao

e15010

Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).

Brunella Di Stefano

3554

Clinicopathologic predictors of worse outcome in early onset colorectal cancer (EO-CRC): A single-institution experience.

Devika Rao

e15064

Colorectal cancer lung metastasis: Could multidisciplinary management suggest the right strategy?

Ina Valeria Zurlo

e15039

Comprehensive transcriptome analysis reveals link between epigenetic dysregulation, endogenous retrovirus expression and immunogenicity in metastatic colorectal carcinoma.

Shehara Ramyalini Mendis

3535

Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO-KRK-0109).

Stefanie Noepel-Duennebacke

e15024

Cost and effectiveness of genetic testing in metastatic colorectal cancer (mCRC) at Montefiore Medical Center (MMC).

Nadia Ashai

e15043

Cost-effectiveness for metastatic colorectal cancer.

Linli Yao

e15003

ctDNA as a potential prognostic marker for locally advanced rectal cancer patients with ‘watch and wait’ approach.

Lifeng Yang

3544

Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18F-FDG PET/CT and clinical factors for metastatic colorectal cancer patients.

Erwin Woff

3543

Effect of acid-reducing agents on the efficacy of capecitabine in metastatic gastrointestinal cancers.

Tonjeh Mary Stella Bah

e15058

Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306).

Volker Heinemann

3541

Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis.

Raffaella Vivolo

e15038

Efficacy of PD-1/PD-L1 inhibitor-based therapies in refractory microsatellite instability (MSI)-unselected metastatic colorectal cancer (mCRC): A network meta-analysis (NMA) of randomized controlled trials (RCTs).

Zi-xian Wang

e15048

Efficacy of quxie capsule in metastatic colorectal cancer: Update of a double-blind, randomized, placebo controlled trial.

Tong Zhang

e15030

Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.

Daniele Rossini

3540

Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.

Ofer Margalit

3539

Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).

Kaysia Ludford

e15046

Evaluation of Dworak grading system as a prognostic indicator after neoadjuvant chemoradiotherapy in rectal cancer patients.

Rebecca Buecker

e15053

Evaluation of long term survival in pretreated metastatic colorectal cancer patients undergoing GOLFIG chemoimmunotherapy regimen.

Pierpaolo Correale

e15057

Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients.

Ina Valeria Zurlo

3558

Feasibility of a national expert panel to determine resectability in patients with initially unresectable colorectal cancer liver metastases (CRLM).

Karen Bolhuis

3562

Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).

Michael Geissler

3511

FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.

Alexandre A Jacome

e15060

Fruquintinib or regorafenib as the third-line treatments for metastatic colorectal cancer based on CONCUR and FRESCO trials: A cost-effectiveness analysis.

Qiu Li

e15011

Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.

Kathrin Heinrich

3559

Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.

Hiroyuki Arai

3545

Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA.

Yoshiaki Nakamura

3528

HD204: Analytical biocomparability and clinical trial I progression of bevacizumab.

Jocelyn hii

e15014

How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis.

Antonio Galvano

e15006

Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.

Federica Marmorino

3536

Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.

Gemma Zucchelli

3534

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia.

Mikhail Fedyanin

e15035

Intratumoral CD3+ and CD8+ T-cell densities in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC) receiving programmed death-1 (PD-1) blockade.

Sakti Chakrabarti

3532

Investigation of an ethnic predisposition to developing brain metastases (BM) in Asian patients with colorectal cancer (CRC).

Kerri McGovern

e15023

Long-term survival after laparoscopic versus open resection for colorectal liver metastases.

Åsmund Avdem Fretland

LBA3516

Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.

Thiru Prasanna

3531

Microsatellite instability and mutations in BRAF and KRAS in small bowel adenocarcinoma.

Vasiliki Michalaki

e15037

Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).

Sukeshi Patel Arora

3551

Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer.

Saivaishnavi Kamatham

e15066

Mutational profiles and amplifications on circulating tumor DNA testing in patients with young-onset colorectal cancer.

Saivaishnavi Kamatham

e15067

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.

Heinz-Josef Lenz

3521

Outcomes of metastatic colorectal cancer over fifteen years from an Indian tertiary care center: A retrospective analysis.

Vinod Sharma

e15050

Patterns of metastasis and second primary malignancies (SPM) in colorectal cancer: A perspective from Peru.

Jorge Leon

e15068

Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal).

Frederic Dumont

e15027

Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.

Ramon Salazar

TPS3618

POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.

David Lau

TPS3615

Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.

Toshiki Masuishi

3560

Predictors of survival in chemorefractory colorectal liver metastases treated with Y90 radioembolization.

Alexander Michael Dabrowiecki

e15044

PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.

Valerie Boige

TPS3619

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.

Julien Taieb

3525

Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs).

Enrique Aranda

3549

Randomized phase II trial of adjuvant hepatic arterial infusion (HAI) + systemic FOLFIRI +/- panitumumab (Pmab) in patients with resected RAS wild type colorectal cancer hepatic metastases (CRLM).

Nancy E. Kemeny

3555

Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).

Javier Sastre

3507

RAS-amplified colorectal cancers: Microsatellite stability status, RAS/BRAF mutations, and prediction of anti-EGFR resistance.

Alexa Betzig Schrock

3533

Recent changes in overall survival of real-life stage IV colorectal cancer patients.

Patricia Hamers

3522

Rectal cancer and pathologic complete response after preoperative chemoradiotherapy: Romanian single-center experience.

Eduard-Alexandru Bonci

e15002

Repeated centralized MDT resectability assessment during first-line treatment in 1086 Finnish metastatic colorectal cancer (mCRC) patients nationwide (prospective RAXO study).

Pia J. Osterlund

3517

Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization.

Robert Asa Horn

e15055

ROCKET: A randomized, multicenter phase 2 study of RRx-001 + irinotecan versus regorafenib in 3rd/4th line colorectal cancer.

Tony R. Reid

3526

Screening patients for fluoropyrimidine-related toxicity risk.

Olivier Capitain

3529

Stereotactic body radiotherapy (SBRT) for colorectal liver metastasis: Clinical outcomes from the international multi-institutional RSSearch Patient Registry.

Pollyanna D'Avila Leite

e15040

Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer.

Stein G Larsen

3565

Survival after primary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (FFCD ACHBTH AURC 9002 trial and EORTC Intergroup trial 40983).

Carl Christoph Schimanski

e15019

Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).

Markus Hermann Moehler

e15025

The “effect” of T classification on colorectal liver metastasis.

Lunpo Wu

e15049

The efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer (ACC) patients: An interim analysis of a multicenter, phase II trial.

Yunpeng Liu

e15061

The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Maryam B. Lustberg

TPS3616

The impact of nodal metastasis on survival in stage IV colon cancer: Analysis of National Cancer Database 2004-2014.

Sukamal Saha

e15042

The role of maintenance strategy in metastatic colorectal cancer (mCRC): A systematic review and meta-analysis.

Mohamad Bassam Sonbol

3524

Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers.

Gemma Bruera

e15013

Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial.

Eiji Oki

3548

Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109).

Dominik Paul Modest

3530

Type 2 diabetes as a potential risk marker for early onset colorectal cancer.

Joanne Young

e15005

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

Chiara Cremolini

3508

Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder.

Reese Garcia

3561

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Franck Pages

3513

Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the MIROX phase III trial.

Samira Makhloufi

3547

Young-onset colorectal cancer patients disproportionately diagnosed with advanced disease: Patient self-reported journey of symptom duration and misdiagnosis.

Ronit Yarden

3567